OncoDaily’s Post

Glad to have co-authored this review with colleagues from the GPCO-Unicancer published in Critical Review in Oncology/Hematology (Elsevier) on optimizing treatments with oral #targeted #therapies in #cancer. Proud to have also my former Ph.D. student Florent Ferrer on board! The article is available at: https://lnkd.in/ei_HQeBB. Enjoy the reading! #oncology #precisionmedicine #pharmacometrics #targetedtherapies

We may be new to LinkedIn, but we've been publishing research for over a year! In our 2023 issue, we published 38 articles that were viewed over 28,000 times by people in more than 165 countries. This year we plan to continue expanding the reach and impact of critical research. Browse our first issue for articles on: - QoL assessment within publications of oncology trials - MRI as a screening tool for prostate cancer - Global trends in early-onset cancer ...And much more! Find the full issue, free to read, right here ⬇️ #BMJOncology #CancerResearch #CancerScreening #CancerTrends

A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC - Elisa Agostinetto JAMA Oncology OncoAlert #BreastCancer #Research #Cancer #HER2E #JAMAOncology #OncoDaily #Oncology #PCR #TumorSubtypes

#Mar2024 Our journal of MAR Oncology & Hematology has been making significant strides, reaching a larger than ever before. It's an achievement we're proud of! Visit Our recent issue release: https://lnkd.in/gu3UFVMR Given your expertise and valuable insights, we would be honored if you could contribute to our next issue on Mar, 01 by submitting an article. Your contribution would not only enhance the quality of our publication but also provide our readers with valuable knowledge and perspectives. Submit your manuscript through this link: https://lnkd.in/gMKTvQAA MedicalandResearchpublications #MARPUBLICATIONS #oncology #lymphoma #cancer #research #hematology #bloodcancer #bloodreports #surgicalinnovation #surgicaloncology #sarcoma

MFS continues to be a reliable predictor for overall survival - Yüksel ÜRÜN #AccessToTreatment #AdjuvantTrials #Cancer #Docetaxel #OncoDaily #Oncology #ProstateCancer 

Oncotarget recently #published this #trendingwithimpact editorial #perspective in Volume 14, entitled, “Genetic modifiers of p53: opportunities for breast cancer therapies." https://lnkd.in/eXdnYAbp #cancer #breastcancer #p53 #dna #tumor #cancercells #oncology #research #cancerresearch #openaccess #openscience #peerreview #journal #publication #publishing #meded #oncotargetshort #video

I discussed the results of our work with Video Journal of Oncology (VJOncology) at ESMOBreast24 - Elisa Agostinetto ESMO - European Society for Medical Oncology Matteo Lambertini Eva Blondeaux Evandro de Azambuja #ESMOBreast24 #BreastCancer #Cancer #OncoDaily #Oncology

A great summary by Priv.-Doz. Dr. med. Niklas Klümper Viktor Grünwald , Viktor Grünwald and team about the role of MMR/MSI - Emre Yekeduz American Society of Clinical Oncology (ASCO) #ASCO #Cancer #MMR #MSI #OncoDaily #Oncology

The ANZUP Cancer Trials Group Limited ASM 2024 Conference Review is out! This review, accompanied by expert commentary by Associate Professor Arun Azad, features articles on; Nurse-led cardio-oncology clinic, A protein signature of metastatic relapse in prostate cancer, and many more!! Read your copy HERE: https://lnkd.in/gytKZwGg #medical #practitioners #conference #oncology #prostatecancer #urogenital #Cancer #review #research

The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story. From its discovery in the 1980s to the groundbreaking advancements in therapy, in this podcast I discuss the nuances of HER2 positive, negative, and the newly recognized HER2-Low category. As we navigate the complexities of breast cancer, it is important to recognize how targeted therapies such as trastuzumab deruxtecan have transformed patient prognoses from the worst to some of the best outcomes in oncology. #BreastCancerAwareness #HER2Low #Oncology #MedicalInnovation #CancerResearch #FDAApproval #DESTINYB04 #ENHERTU #TrastuzumabDeruxtecan #BreastCancer